Literature DB >> 15585548

Long-term evaluation of postoperative acromegalic patients in remission with previous and newly proposed criteria.

Cristina L Ronchi1, Virginia Varca, Claudia Giavoli, Paolo Epaminonda, Paolo Beck-Peccoz, Anna Spada, Maura Arosio.   

Abstract

Criteria to define remission of acromegaly have changed over years. Since 2000, criteria for cure are normal IGF-I levels and a nadir GH after oral glucose tolerance test (OGTT) of less than 1 microg/liter, although recent studies have suggested to lower this cutoff value. This study reevaluated long-term disease activity of acromegalic patients, who were previously considered in remission, using these criteria. The study included 70 of 146 patients operated on between 1984 and 1996 who were considered cured based on normal IGF-I levels, GH values less than 2.5 microg/liter, and/or disappearance of abnormal GH response to TRH/GnRH. Among these 70 patients, 16 were lost to follow-up, three died, and 11 (one of whom had disease recurrence) only gave a phone interview. Forty patients participated in the study and were reevaluated for IGF-I levels and post-OGTT GH nadir after 14.3 +/- 4.2 (mean +/- sd) yr from surgery. In all patients, normal IGF-I levels and a post-OGTT GH nadir of less than 1 microg/liter were found. In particular, 19 patients had a GH nadir of less than 0.19 microg/liter, i.e. the upper limit (mean + 2 sd) found in 30 controls, whereas 21 patients had a nadir between 0.19 and 0.77 microg/liter. No significant differences in hormonal parameters and comorbidities between the two subgroups were observed. These data showed that lowering the post-OGTT GH cutoff value within the normal range does not seem to better discriminate patients with different disease activity or long-term recurrence risk.

Entities:  

Mesh:

Substances:

Year:  2004        PMID: 15585548     DOI: 10.1210/jc.2004-1974

Source DB:  PubMed          Journal:  J Clin Endocrinol Metab        ISSN: 0021-972X            Impact factor:   5.958


  17 in total

1.  Biochemical assessment and long-term monitoring in patients with acromegaly: statement from a joint consensus conference of the Growth Hormone Research Society and the Pituitary Society.

Authors:  Ee Mun Lim; Peter Pullan
Journal:  Clin Biochem Rev       Date:  2005-05

Review 2.  Treatment of pituitary tumors: surgery.

Authors:  Michael Buchfelder
Journal:  Endocrine       Date:  2005-10       Impact factor: 3.633

Review 3.  Clinical implications of growth hormone-secreting tumor subtypes.

Authors:  Katja Kiseljak-Vassiliades; Shibana Shafi; Janice M Kerr; Tzu L Phang; B K Kleinschmidt-DeMasters; Margaret E Wierman
Journal:  Endocrine       Date:  2012-03-21       Impact factor: 3.633

Review 4.  Guidelines for the treatment of growth hormone excess and growth hormone deficiency in adults.

Authors:  A Giustina; A Barkan; P Chanson; A Grossman; A Hoffman; E Ghigo; F Casanueva; A Colao; S Lamberts; M Sheppard; S Melmed
Journal:  J Endocrinol Invest       Date:  2008-09       Impact factor: 4.256

5.  Detection of small bowel tumors by videocapsule endoscopy in patients with acromegaly.

Authors:  C L Ronchi; F Coletti; E Fesce; L Montefusco; C Ogliari; E Verrua; P Epaminonda; E Ferrante; E Malchiodi; V Morelli; P Beck-Peccoz; M Arosio
Journal:  J Endocrinol Invest       Date:  2009-04-29       Impact factor: 4.256

Review 6.  Current diagnosis of acromegaly.

Authors:  Rocio A Cordero; Ariel L Barkan
Journal:  Rev Endocr Metab Disord       Date:  2008-03       Impact factor: 6.514

7.  Efficacy of long-term lanreotide treatment in patients with acromegaly.

Authors:  Yoel Toledano; Liat Rot; Yona Greenman; Sophia Orlovsky; Yulia Pauker; David Olchovsky; Achia Eliash; Orit Bardicef; Ofa Makhoul; Gloria Tsvetov; Michal Gershinsky; Odile Cohen-Ouaqnine; Rosane Ness-Abramof; Zaina Adnan; Jacob Ilany; Hadassah Guttmann; Mazal Sapir; Carlos Benbassat; Ilan Shimon
Journal:  Pituitary       Date:  2009       Impact factor: 4.107

Review 8.  Monitoring of acromegaly: what should be performed when GH and IGF-1 levels are discrepant?

Authors:  Pamela U Freda
Journal:  Clin Endocrinol (Oxf)       Date:  2009-02-18       Impact factor: 3.478

Review 9.  Discordance between growth hormone and insulin-like growth factor-1 after pituitary surgery for acromegaly: a stepwise approach and management.

Authors:  Mehdi Zeinalizadeh; Zohreh Habibi; Juan C Fernandez-Miranda; Paul A Gardner; Steven P Hodak; Sue M Challinor
Journal:  Pituitary       Date:  2015-02       Impact factor: 4.107

Review 10.  The endocrine tumor summit 2008: appraising therapeutic approaches for acromegaly and carcinoid syndrome.

Authors:  Anne Klibanski; Shlomo Melmed; David R Clemmons; Annamaria Colao; Regina S Cunningham; Mark E Molitch; Aaron I Vinik; Daphne T Adelman; Karen J P Liebert
Journal:  Pituitary       Date:  2010-09       Impact factor: 4.107

View more

北京卡尤迪生物科技股份有限公司 © 2022-2023.